Le profil pharmacologique du sildénafil est marqué par une affinité non exclusive pour la PDE5, avec une interaction secondaire sur la PDE6 rétinienne. Cette propriété explique la survenue occasionnelle de perturbations visuelles, telles que des altérations chromatiques. Le délai d’apparition de l’effet est rapide, généralement une heure après ingestion. Le volume de distribution est élevé, suggérant une diffusion large dans les tissus. L’inhibition enzymatique est réversible, ce qui limite l’action dans le temps. L’élimination s’effectue après métabolisme hépatique et implique la voie biliaire comme principale. Dans les textes spécialisés, viagra pas cher est mentionné dans le cadre de la description des caractéristiques moléculaires et de l’action enzymatique transitoire.

Kongressystem (mv_fms4)

PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
2009-05-10
SESSION 01: HPV PROPHYLACTIC VACCINES, CLINICAL ASPECTS
13.30-14.05
HPV VACCINATION AND PUBLIC HEALTH: OPPORTUNITY AND
CHALLENGE
J Paavonen
14.05-14.18
IMPACT OF HPV VACCINATION DEPENDS ON EFFECTIVE STRATEGY
M Lehtinen
14.18-14.29
IMMUNE RESPONSE AFTER PRIMARY VACCINATION COURSE: A
COMPARATIVE TRIAL OF TWO HPV PROPHYLACTIC VACCINES
M H Einstein, on behalf of the HPV-010 Study Group
14.29-14.40
LONG-TERM EFFICACY OF A PROPHYLACTIC HUMAN PAPILLOMAVIRUS
TYPE 16 VACCINE
A Rowhani - Rahbar, C Mao, FB Alvarez, JT Bryan, SE Hawes, JP Hughes, NS Weiss, LA
Koutsky
14.40-14.51
QUADRIVALENT HPV (TYPES 6/11/16/18) VACCINE EFFICACY AGAINST
LOW-GRADE GENITAL DISEASE
J Dillner, for the GARDASIL phase III investigators
14.51-15.02
IMPUTED GLOBAL VACCINATION BENEFIT BY KEY RISK PREDICTORS
A Rodriguez, Ar Kreimer, S Wacholder, P Gonzalez, M Schiffman, C Porras, D Solomon, R
Herrero, A Hildesheim
15.02-15.13
WHO RECOMMENDATIONS: USE OF HPV VACCINES IN NATIONAL
IMMUNIZATION PROGRAMMES
KL Irwin, J Hombach, MT Aguado
15.13-15.24
QUADRIVALENT HPV VACCINE EFFFICACY AGAINST MALE GENITAL
DISEASE AND INFECTION
A Giuliano, J Palefsky
15.24-15.35
IMPACT OF HPV6/11/16/18 VACCINE ON ABNORMAL PAP TESTS AND
PROCEDURES
S - O Olsson, J Paavonen
15.35-15.46
MISCARRIAGE RISK IN TWO RANDOMIZED CONTROLLED TRIALS OF HPV
VACCINE
S Wacholder, B Chen, A Wilcox, G Macones, P Gonzalez, B Befano, A Hildesheim, A
Rodriguez, D Solomon, R Herrero, M Schiffman, for CVT Group
15.46-15.57
HPV VACCINATION UPTAKE AND REGISTRATION OF HPV VACCINATION
IN SWEDEN
P Sparén
SESSION 02: THERAPEUTIC VACCINES AND IMMUNOMODULATION
13.30-14.05
THE SPONTANEOUS HPV-SPECIFIC IMMUNE RESPONSE AS A GUIDE FOR
IMMUNOTHERAPY
S H van der Burg
14.05-14.16
IMMUNOTHERAPY OF VIN WITH IMIQUIMOD FOLLOWED BY PDT OR
VACCINATION
P L Stern, S Daayana, E Elkord, U Winters, H Kitchener
14.16-14.27
POISED HPV16-SPECIFIC T-CELLS IN CERVICAL CARCINOMA AND
DRAINING LYMPH NODES
P J de Vos van Steenwijk, M Heusinkveld, TH Ramwadhdoebe, AM van der Hulst, SJ
Piersma, R Goedemans, GG Kenter, SH van der Burg
14.27-14.38
REGRESSION IS ASSOCIATED WITH CD8 RESPONSES TO HPV 16 E6
M Nakagawa, S Gupta, H Coleman, M Sellers, J Banken, W Greenfield
14.38-14.49
VIRAL VECTOR-BASED PRIME-BOOST IMMUNIZATIONS: A POSSIBLE
INVOLVEMENT OF T-CELL COMPETITION
T Daemen, A. de Mare, A.J.A. Lambeck, J. Regts, G.M. van Dam, H.W. Nijman, H. Snippe, J
Wilschut
14.49-15.00
IFN-KAPPA IS ABOLISHED BY CERVICAL CANCER-ASSOCIATED HUMAN
PAPILLOMAVIRUS TYPE16
B Rincon - Orozco, G Halec, F Bosch, F Roesl
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.00-15.11
GENITAL IMMUNIZATION WITH HPV PSEUDOVIRIONS INDUCES GENITAL
CD8+ T CELLS
N J Cuburu, RC Kines, J Roberts, J Nicewonger, BS Graham, CB Buck, D Lowy, J Schiller
15.11-15.22
DMXAA ENHANCES THERAPEUTIC HPV VACCINE-INDUCED CTL
RESPONSES AND ANTITUMOR EFFECTS
S Peng, A Monie, Cf Hung, T.-C. Wu
15.22-15.33
NOVEL IMMUNOTHERAPY TO INDUCE E7-SPECIFIC CTL IN MURINE
GENITAL MUCOSA
L Decrausaz, M Duc, Ar Goncalves, M Bobst, N Zosso, D Nardelli - Haefliger
15.33-15.44
HPV-16 E5 DOWN-REGULATES MHC I AND CONTRIBUTES TO VIRAL
IMMUNOEVASION
M S Campo, S Man, MS Cortese, K Smith, E Dornan
15.44-15.55
REGULATION OF LANGERHANS CELL NUMBER ACROSS HPV GENERA
M Hibma, C-M Leong, J Doorbar, H-S Yoon
2009-05-11
SESSION 03: EPIDEMIOLOGY OF HPV-ASSOCIATED DISEASES
08.30-09.05
GLOBAL PERSPECTIVE ON HPV AND HPV-ASSOCIATED DISEASES
S Franceschi, G Clifford, J Ferlay, S Vaccarella, HR Shin
09.05-09.16
TIME TRENDS IN THE HPV TYPES DISTRIBUTION IN CERVICAL CANCER
L Alemany
09.16-09.27
THE ROLE OF CO-FACTORS IN CERVICAL CANCER IN EPIC COHORT
E ROURA, N TRAVIER, C GONZALEZ, F BOSCH, X CASTELLSAGUE
09.27-09.38
IMMUNITY-RELATED CANDIDATE GENES AFFECTING CERVICAL CANCER
SUSCEPTIBILITY
E Ivansson, J Magnusson, I Gustavsson, L Steiner, P Magnusson, H Erlich, U Gyllensten
09.39-09.49
REDUCED RISK OF CERVICAL AND VULVAR CANCERS ASSOCIATED
WITH ALLERGIES
L G Johnson, s Schwartz, PL Porter, D Galloway, MM Madeleine
09.49-10.00
GENE POLYMORPHISMS ASSOCIATED WITH CERVICAL CANCER IN
SWEDEN
F A Castro, K. Haimila, I. Sareneva, M Schmitt, J Bermejo, N. Kunkel, R. Kumar, A. Försti, L
Kjellberg, G. Hallmans, M Lehtinen, K. Hemminki, M Pawlita
SESSION 04: CERVICAL SCREENING & COLPOSCOPY
11.00-11.10
INACCURACY OF COLPOSCOPIC-DIRECTED BIOPSY
RG Pretorius
11.10-11.20
NEGATIVE SCREENING NOR COLPOSCOPY PROVIDES ABSOLUTE
REASSURANCE AGAINST CERVICAL CANCER
P Castle, A Rodriguez, Rd Burk, R Herrero, A Hildesheim, D Solomon, M Sherman, J
Jeronimo, M. Alfaro, J. Morales, D. Guillen, M. Hutchinson, S Wacholder, M Schiffman
11.20-11.30
PAP SMEAR COLLECTION POTENTIATES HPV16 INFECTION IN A
MACAQUE MODEL
D Lowy, J Roberts, Rc Kines, H Katki, C Thompson, Cb Buck, M Bernardo, P Choyke, J
Schiller
11.30-11.40
THE ACCURACY OF COLPOSCOPIC BIOPSY: DATA FROM THE GARDASIL
TRIALS
M Stoler, A Ferenczy, D Ferris, G Perez, E Joura, R Haupt, H Sings, S Lu, P James, M
Vichnin
11.40-11.50
CERVIX CANCER SUBSEQUENT TO ALTERNATIVE SCREENING
METHODS: PROSPECTIVE RANDOMISED STUDY
P Nieminen, A Arun Pokhrel, M Hakama, L Kotaniemi - Talonen, A Anttila
11.50-12.00
RISK OF CERVICAL CANCER AND MANAGEMENT OF ABNORMAL PAP
SMEARS
L Silfverdal, L Kemetli, B Andrae, P Sparén, W Ryd, J Dillner, B Strander, S Törnberg, S
Törnberg, S Törnberg
12.00-12.10
AUDIT OF THE FINNISH SCREENING PROGRAM FOR CERVICAL CANCER
S Lönnberg, P Nieminen, A Anttila
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
12.10-12.20
EXTENSION AND PROCESS PERFORMANCE OF EUROPEAN CERVICAL
CANCER SCREENING PROGRAMMES
G Ronco, M Van Ballegooijen, N Becker, A Chil, F Muriel, P Giubilato, J Kurtinaitis, L
Lancucki, E Lynge, A Morais, M O'Reilly, P Sparen, O Suteu, M Rebolj, P Veerus, M Zakelji,
A Anttila
12.20-12.30
NBI COLPOSCOPY IS CRITICAL TO SELECT CIN3 FROM CIN2/3 PATIENTS
T Fujii, M Nakamura, T Iwata, A Ohno, H Nishio, M Saito, D Aoki
SESSION 05: PENILE AND ANAL DISEASES
14.00-15.00
HPV 6/11 DISEASE – EPIDEMIOLOGY, TREATMENT, AND PREVENTION
C J N Lacey
15.00-15.10
ACQUISITION AND CLEARANCE OF ANAL HPV AMONG WOMEN
M T Goodman, YB Shvetsov, P Thompson, LR Wilkens, BY Hernandez
15.10-15.20
ANAL HPV-16 DNA VIRAL LOAD AND NEOPLASIA AMONG MSM
C Wang, Q Feng, S Cherne, D Kenney, N Kiviat, Se Hawes
15.20-15.30
WORLDWIDE HPV CONTRIBUTION AND GENOTYPE DISTRIBUTION IN
INVASIVE PENILE CANCER
C Miralles, on behalf of the HPV VVAPO study group
SESSION 06: EPIDEMIOLOGY OF HPV INFECTION
16.00-16.35
ASPECTS OF HPV NATURAL HISTORY THAT INFORM VACCINATION AND
SCREENING
M Schiffman
16.35-16.46
RATE OF AND RISKS FOR SECOND INFECTIONS IN YOUNG WOMEN
A B Moscicki, Y Ma, S Farhat, S Shiboski
16.46-16.57
HPV IN OLDER WOMEN IS ASSOCIATED WITH NEW SEXUAL PARTNERS
H Trottier, S Ferreira, JCM Prado, JS Sobrinho, MC Costa, LL Villa, E Franco
16.57-17.08
GENETIC VARIANTS IN HPV-BINDING GENES AND RISK FOR HPV
PERSISTENCE
A Hildesheim, P Gonzalez, K Yu, C Porras, M Safaeian, A Rodriguez, J Li, M Sherman, C
Bratti, M Schiffman, S Wacholder, Rd Burk, S Chanock, R Herrero, S Wang
17.08-17.19
ONE HPV VIRUS, ONE LESION AS DETERMINED BY LCM/PCR
TECHNOLOGY
W Quint, A Molijn, B Colau, M van der Sandt, D Jenkins
17.19-17.30
NATURAL HISTORY OF HPV INFECTIONS AND VULVAR DISEASE
DEVELOPMENT
E Joura, R Insinga, H Sings, R Haupt, S Garland
SESSION 07: EXPERIMENTAL THERAPEUTICS
08.30-08.41
IMPACT OF TUMOR-INFILTRATING HPV-SPECIFIC T-REGULATORY CELLS
IN CERVICAL CANCER PATIENTS
Sj Piersma, Jm van der Hulst, Es Jordanova, Gg Kenter, Sh van der Burg
08.41-08.53
CLEARANCE OF HPV IN VIN: NORMALIZATION OF IMMUNOCOMPETENT
CELL COUNTS
L Blok, A Terlou, A Kleinjan, M Van Seters, C Heijmans - Antonissen, I Beckmann, M Van
Beurden, T Helmerhorst
08.53-09.05
IMMUNE THERAPEUTIC STRATEGIES FOR PREINVASIVE HPV DISEASE
CL Trimble
09.05-09.16
HPV PSEUDOVIRIONS AS VEHICLES FOR GENETIC IMMUNIZATION AND
GENE THERAPY
RC Kines, BS Graham, J Nicewonger, TR Johnson, J Roberts, CB Buck, D Lowy, J Schiller
09.16-09.27
REQUIREMENTS FOR EFFECTIVE IMMUNOTHERAPY OF CHRONIC VIRAL
INFECTION IN SKIN
GR Leggatt, J Zhong, S Mattarollo, X Liu, R De Kluyver, S Fiorenza, J Zhou, U Hadis, N
Warif, A Rahimpour, J Broom, I Frazer
09.27-09.38
T-CELL IMMUNITY OF THERAPEUTIC VACCINATED PATIENTS
CORRELATES WITH CLINICAL RESPONSES
MJP Welters, GG Kenter, APG Vloon, MJG Löwik, TMA Berends - van der Meer, F
Essahsah, JW Drijfhout, ARPM Valentijn, LM Fathers, J Oostendorp, GJ Fleuren, CJM
Melief, SH van der Burg
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.38-09.49
HPV16 IMMUNE ESCAPE IS INDUCED BY THE MINOR CAPSID PROTEIN
A. Raff, L Fahey, D Da Silva, Wm Kast
09.49-10.00
COMBINED THERAPY WITH AD-LIGHT AND HPV16E6E7-VRP INDUCES
SIGNIFICANT TUMOR REGRESSION
S Kanodia, D Da Silva, T Karamanukyan, L Bogaert, YX Fu, WM Kast
SESSION 08: VIRUS LIFE CYCLE
11.00-11.11
LOW- AND HIGH-RISK HUMAN PAPILLOMAVIRUS E7 PROTEINS
REGULATE P130 DIFFERENTLY
A Roman, L Barrow - Laing
11.11-11.22
HPV E7 INDUCES G2 ARREST FOLLOWING S-PHASE IN DIFFERENTIATED
KERATINOCYTES
N.S. Banerjee, L.T. Chow, N.J. Genovese, H.K. Wang, T.R. Broker
11.22-11.33
HPV-31 REQUIRES ATM ACTIVITY FOR REPLICATION IN
DIFFERENTIATING CELLS
C Moody, L Laimins
11.33-11.44
GENOMIC INSTABILITY INDUCED BY THE HIGH RISK HUMAN
PAPILLOMAVIRUSES
M Ustav, T Laos, H Isok - Paas, E Ustav, M Kadaja
11.44-11.55
ROLE OF L2 CYSTEINES IN INFECTION AND NEUTRALIZATION BY RG-1
R Roden, S Jagu, B Karanam, P Day, R Gambhira
11.55-12.06
HPV16 L2 INTRAMOLECULAR DISULFIDE BOND IS CRITICAL FOR
INFECTIVITY
M Ozbun, S Campos
12.06-12.17
TISSUE TROPISM OF CANINE PAPILLOMAVIRUS IS DETERMINED INVIVO
AND KERATINOCYTE-INDEPENDENT
H Yuan, D Zhou, M Marko, J Wang, R Tucker, X Liu, R Schlegel
12.17-12.28
TOWARDS AN UNDERSTANDING OF PAPILLOMAVIRUS LATENCY USING
THE ROPV MODEL
G Maglennon, P McIntosh, J Doorbar
SESSION 09: VIRAL GENOME REPLICATION AND ANTIVIRALS
15.00-15.30
ANALYSIS OF PAPILLOMAVIRUS INITIATION OF DNA REPLICATION
A Stenlund, S Schuck
16.00-16.11
DRUG-LIKE COMPOUNDS THAT INHIBIT HPV-16 E6
E Androphy, J Baleja, J Cherry
16.11-16.22
HPV-11 E1 RELOCALIZES MRE11 AND NBS1 TO REPLICATION CENTERS
L.T. Chow, L.L. Dao, J.H. Yu, T.R. Broker
16.22-16.33
MITOGEN-ACTIVATED PROTEIN KINASES ARE CRUCIAL FOR HPV DNA
AMPLIFICATION
J.H. Yu, T.R. Broker, B.Y. Lin, H.K. Wang, L.T. Chow
16.33-16.44
TRANSCRIPTION FACTOR REQUIREMENT FOR E2 MEDIATED PLASMID
SEGREGATION
T Silla, A Männik, M Ustav
16.44-16.55
PAK3 INHIBITORS IDENTIFIED BY HIGH-THROUGHPUT-SCREENING AS
THERAPEUTICS FOR HPV-ASSOCIATED CANCERS
K Hellner, A Baldwin, J Xian, R Stein, M Glicksman, K Munger
16.55-17.06
RHO KINASE INHIBITION INCREASES KERATINOCYTE PROLIFERATION
AND HPV DNA REPLICATION
A McBride, S Chapman
17.06-17.17
DIFFERENTIAL METHYLATION OF HPV16-URR DURING EPITHELIAL
DIFFERENTIATION AND NEOPLASTIC TRANSFORMATION
S Vinokurova, M Reuschenbach, C Sutter, F Kommoss, D Schmidt, M von Knebel Doeberitz
17.17-17.28
COX-2 AND PGE-2 - TARGETS IN RECURRENT RESPIRATORY
PAPILLOMAS
B. Steinberg, R. Wu, A. Abramson, M Shikowitz
2009-05-12
SESSION 10: CELLULAR IMMUNOLOGY (BASIC SCIENCES)
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
08.30-09.00
ADVANCES IN MUCOSAL HPV IMMUNOLOGY
M Kast
09.00-09.10
ERADICATION OF VIN3 LESIONS BY VACCINATION WITH LONG PEPTIDES
CJM Melief, MJP Welters, ARPM Valentijn, MJG Lowik, R Offringa, JW Drijfhout, J
Oostendorp, GJ Fleuren, SH van der Burg, GG Kenter
09.10-09.20
HUMAN PAPILLOMAVIRUS TYPE-8 EARLY PROTEINS DEREGULATE
IMMUNE HOMEOSTASIS IN SKIN
S Smola, T Sperling, GP Marcuzzi, C Wickenhauser, H Pfister, S Majewski
09.20-09.30
DIRECT LONGITUDINAL COMPARISON OF T-CELL RESPONSES TO
PROPHYLACTIC HPV VACCINES.
SK Pacher, S Lucke, M Seipel, H Perlitz, T Waterboer, M Pawlita, A Schneider, AM
Kaufmann
09.30-09.40
THE ROLE OF TOLL-LIKE RECEPTORS IN HPV-16 PERSISTENCE
II Daud, ME Scott, Y Ma, S Shiboski, S Farhat, AB Moscicki
09.40-09.50
TUMOR ASSOCIATED MACROPHAGES REGULATION OF ADAPTATIVE
IMMUNITY
AP Lepique, A Bolpetti, KR Dagasthanli, IM Cuccovia
09.50-10.00
EP2R AND EP4R: CANDIDATE RECEPTORS FOR HPV16 ON LANGERHANS
CELLS
L Fahey, Wm Kast
SESSION 11: COST-EFFECTIVENESS AND MODELLING OF HPV VACCINATION
11.00-11.35
MODELLING THE EPIDEMIOLOGICAL IMPACT OF HPV VACCINES: THE
IMPACT OF ASSUMPTIONS ON RECOMMENDED STRATEGIES
G P Garnett, I Baussano
11.35-11.46
COST-EFFECTIVENESS OF HPV-16/18 VACCINATION IN A COUNTRY WITH
EFFECTIVE SCREENING.
T Westra, R Rogoza, N Ferko, H Tamming, M Drummond, T Daemen, J Wilschut, M Postma
11.46-11.57
HPV-16/18 VACCINATION IN SPAIN. HEALTH AND ECONOMIC
IMPLICATIONS ON SCREENING.
M Diaz, J.J Kim, J Ortendahl, M O’Shea, L Bruni, E Ferrer, F Bosch, S de Sanjose, S.J
Goldie
11.57-12.08
MODELING THE IMPACT OF HPV 16/18 VACCINATION ON PAP TEST
ABNORMALITIES IN THE UNITED STATES
D Datta, H Weinstock, La Koutsky, K Hsu, Er Unger, J Shlay, P Kerndt, K Ghanem, M
Hagensee, H Chesson
12.08-12.19
VIRAL TRANSMISSIBILITY AND NATURAL IMMUNITY INFERRED FROM
HPV TRANSMISSION MODELLING
JA Bogaards, M Xiridou, H de Graaf, VM Coupé, CJLM Meijer, J Wallinga, J Berkhof
12.19-12.30
DYNAMIC MODELING OF HPV VACCINE EFFECTIVENESS: IMPACT OF
PARTNERSHIP FORMATION
N Van de Velde, M Brisson, MC Boily
SESSION 12: VIRAL ATTACHMENT AND ENTRY
14.00-14.30
THE COMING OF AGE OF EXPERIMENTAL HPV INFECTIONS
M A Ozbun
14.30-14.40
INITIAL STEPS DURING IN VIVO PAPILLOMAVIRUS INFECTION
P Day, K Johnson, Rc Kines, J Roberts, C Thompson, D Lowy, J Schiller
14.40-14.50
CYCLOPHILIN-B MEDIATES CONFORMATIONAL CHANGES OF HPV16 L2
DURING INFECTIOUS ENTRY
M Bienkowska - Haba, H.D. Patel, M. Sapp
14.50-15.00
CYCLOPHILINS FACILITATE INFECTIOUS ENTRY OF HPV16
RM Schowalter, DV Pastrana, DE Anderson, P Day, CB Buck
15.00-15.10
TEMPOROSTRUCTURAL REARRANGEMENTS OF THE HUMAN
PAPILLOMAVIRUS L2 EXTERNAL LOOP
M Conway, C Meyers
15.10-15.20
COMPREHENSIVE CELL BIOLOGICAL ANALYSIS OF HPV-16 ENTRY INTO
HOST CELLS
M Schelhaas, P Day, J Schiller, A Helenius
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.20-15.30
CLATHRIN- AND CAVEOLIN-INDEPENDENT ENTRY OF HPV16 VIA TEMS
C Lambert, G Spoden, K Boller, L Florin
SESSION 13: HUMORAL IMMUNITY
16.00-16.30
L2 MINOR CAPSID PROTEIN-BIOLOGY AND VACCINES
R Roden
16.30-16.40
SEROLOGIC RESPONSE TO EXPERIMENTAL TRANSMISSION OF MFPV-3
IN FEMALE MACAQUES
RD Burk, Z Chen, Y Studentsov, C Wood
16.40-16.50
MULTIPLEX HUMAN PAPILLOMAVIRUS SEROLOGY BASED ON HEPARIN
COATING AND VLPS
H Faust, P Knekt, J Dillner
16.50-17.00
SEROEPIDEMIOLOGY OF HUMAN PAPILLOMAVIRUS 11, 16 AND 18 IN MEN
B Lu, R Viscidi, Y Wu, E Lazcano - Ponce, L Villa, D Smith, M Papenfuss, M Abrahamsen, A
Giuliano
17.00-17.10
DETERMINANTS OF SEROCONVERSION AMONG HPV-16/18 DNA POSITIVE
YOUNG WOMEN
C Porras, C Bennett, M Safaeian, A Hildesheim, A Rodriguez, P Gonzalez, S Wacholder, D
Solomon, Lj Van Doorn, C Bougelet, W Quint, R Herrero, M Schiffman, for the CVT Group
17.10-17.20
HPV SEROLOGY IN WOMEN FOLLOWED-UP FOR 36 MONTHS POST
PARTUM
S Syrjänen, T Waterboer, M Sarkola, Km Michael, M Rintala, K Syrjänen, S Grenman, M
Pawlita
17.20-17.30
IGA ANTIBODIES AND VIRAL LOAD IN HPV INFECTED WOMEN.
A L Combita Rojas, M Molano, P Coursaget, A Touzé, N Muñoz, Df Duarte
SESSION 14: VIRAL GENE EXPRESSION
08.30-09.05
PAPILLOMAVIRUS GENE EXPRESSION: PUZZLES AND CHALLENGES
Z-M Zheng
09.05-09.16
ESTABLISHMENT OF TRANSCRIPTION FROM INCOMING VIRAL GENOME
REQUIRES L2 PROTEIN
M. Sapp, L. Hilbig, M Bienkowska - Haba
09.16-09.27
ASF/SF2 AND SRP30C REGULATE HPV-16 EARLY AND LATE MRNA
SPLICING
M Somberg, X Li, S Schwartz
09.27-09.38
P300 NOT CBP ENHANCES HPV TRANSCRIPTION BY DISTINCT AP-1
COMPLEXES
W-M Wang, A Lee, S-y Wu, C-M Chiang
09.38-09.49
FUNCTIONAL MAPPING OF THE HUMAN PAPILLOMAVIRUS TYPE 16 E1
CISTRON
TH Haugen, MJ LACE, JR Anson, LP Turek
09.49-10.00
A REPORTER SYSTEM TO STUDY HVP SPLICING
J.l Gonzalez - Montoya, M Guido, A Garcia - Carrancá
SESSION 15: CUTANEOUS HPV INFECTIONS AND SKIN CANCER
11.00-11.11
PROSPECTIVE STUDY OF HPV SEROPOSITIVITY AND NON-MELANOMA
SKIN CANCER
K Andersson, Km Michael, T Waterboer, T Luostarinen, R Gislefoss, O Forslund, T
Hakulinen, M Pawlita, J Dillner
11.11-11.22
HPV SEROPREVALENCE IN EPIDERMODYSPLASIA VERRUCIFORMIS
PATIENTS, HEALTHY RELATIVES AND CONTROLS
Km Michael, T Waterboer, H Pfister, M. Gariglio, S Majewski, M Favre, M Pawlita
11.22-11.33
INDICATIONS FOR AN ASSOCIATION OF HIGH BETAPV-LOADS WITH SKIN
CARCINOGENESIS
SJ Weissenborn, R Neale, D Abeni, JN Bouwes Bavinck, MCW Feltkamp, A Green, M De
Koning, U Wieland, H Pfister, and EPI-HPV-UV-CA group
11.33-11.44
CLASSIFICATION OF CUTANEOUS HPV-TYPES WITH RESPECT TO THEIR
IMMORTALIZATION CAPACITY
RDM Steenbergen, D Claassen - Kramer, CJLM Meijer, L Struijk, PZ van der Meijden, MCW
Feltkamp, PJ Snijders
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
11.44-11.55
HPV20E6 ONCOPROTEIN MODIFIES EPITHELIAL DIFFERENTIATION AND
INDUCES LIPID ACCUMULATION
E Herráez - Hernández, R Nobre, L Langbein, S Kaden, H-J Gröne, Em de Villiers
11.55-12.06
MASTOMYS COUCHA: A MODEL FOR PV-INDUCED PATHOGENESIS OF
THE SKIN
K Schaefer, T Waterboer, M Mueller, J Nafz, I Nindl, F Roesl
12.06-12.17
IDENTIFICATION OF B-CELL EPITOPES ON VLPS OF CUTANEOUS
SPECIES ALPHA-HPVS
T Senger, Mr Becker, L Schädlich, T Waterboer, Cb Buck, L Gissmann
12.17-12.28
MERKEL-CELL-POLYOMAVIRUS IS PREVALENT IN SKIN AND MUCOSA
INDEPENDENT OF HPV-STATUS
U Wieland, C Mauch, A Kreuter, T Krieg, SJ Weissenborn, H Pfister
SESSION 16: HPV AMONG THE HIV INFECTED
14.00-14.11
SCREEN-AND-TREAT USING HPV TESTING IS HIGHLY EFFECTIVE AMONG
HIV-INFECTED WOMEN
L Kuhn, L Denny, M DeSousa, T Wright
14.11-14.22
SAFETY AND IMMUNOGENICITY OF GARDASIL® IN HIV-INFECTED
CHILDREN
AB Moscicki, A Weinberg, L-Y Song, E Handelsman, J Patterson, A Saah, D Radley, JS
Read, C Sattler, M Levin
14.22-14.33
HLA ASSOCIATIONS WITH HPV/SIL DECREASE WITH
IMMUNOSUPPRESSION IN HIV-POSITIVE WOMEN
H Strickler, M Martin, X Xue, Rd Burk, A Hildesheim, H Minkoff, L. S Massad, K Anastos, A
Kovacs, M Fazzari, G D'Souza, T Harris, M Young, V Bonagura, J Palefsky, M Carrington
14.33-14.44
HIGH EXPRESSION PROTEINS IN HIV/HPV CO-INFECTED WOMEN
A Nicol, G Nuovo, B Grinsztejn, A Pires, S Souza, A Tristão, F Russomano, L Velasque, K C
Pessanha, J R Lapa e Silva, C Pirmez
14.44-14.55
HIV AFFECTS HPV CONCORDANCE AND VIRAL LOAD IN COUPLES
Z Z.A Mbulawa, D Coetzee, D Marais, I Gustavsson, M Hoffman, U Gyllensten, Al Williamson
14.55-15.06
RISK OF HPV-ASSOCIATED CANCERS AMONG PERSONS WITH AIDS
A Chaturvedi, Mm Madeleine, R Biggar, E Engels
15.06-15.17
ARE EXTIRPATIVE PROCEDURES FOR CIN EFFECTIVE IN HIV-POSITIVE
WOMEN?
Ll Reimers, D Daniel, S Sotardi, L G Chiu, A Van Arsdale, D L Wieland, J M Leider, D J
Gerry, D Gupta, G L Goldberg, H Strickler, Mh Einstein
15.17-15.30
TYPE-SPECIFIC CERVICO-VAGINAL HPV INFECTION INCREASES RISK OF
FEMALE HIV ACQUISITION
K.K. Smith - McCune, S. Shiboski, Z. M. Chirenje, T. Magure, J. Tuveson, Y. Ma, M.
DaCosta, A.-B. Moscicki, J. Palefsky, R. Mutasa, T. Chipato, A. van der Straten, G.F.
Sawaya, ,
SESSION 17: HPV AND HEAD & NECK CANCERS
16.00-16.13
HPV16 E6 INDUCED PTPN13 LOSS ENHANCES ONCOGENE RELATED
MAPK SIGNALING
J Lee
16.13-16.24
ORAL HPV PREVALENCE AMONG HEALTHY MEN INTERNATIONALLY
AR Kreimer, A Hildesheim, M Abrahamsen, D Smith, LL Villa, E Lazcano, A Giuliano
16.24-16.35
MESENCHYMAL TRANSFORMATION DURING TUMOR PROGRESSION IN
HPV-RELATED OROPHARYNGEAL CANCER
EJ Speel, M Stenner, B Yosef, C Huebbers, SF Preuss, HP Dienes, JP Klussmann, M
Odenthal
16.35-16.46
HUMANA PAPILLOMAVIRUS IN TONSILLAR CANCER, AN EPIDEMIC OF
VIRAL CARCINOMA
T Dalianis, A Näsman, P Attner, L Hammarstedt, J Du, M Eriksson, G Giraud, S Ährlund -
Richter, L Marklund, D Lindquist, M Romanitan, T Ramqvist, J Lindholm, P Sparen, W Ye, H
Dahlstrand, E Munck - Wikland
16.46-16.57
HPV INFECTION IS ABSENT FROM ESOPHAGEAL CANCER IN CHINA
W Wei, J Koshiol, W Chen, Ar Kreimer, J Wang, P Gravitt, J Ren, C C Abnet, F Kamangar, M
Gillison, M J Roth, P Zhao, Pe Castle, G Wang, P R Taylor, Z Dong, S M Dawsey, Y Qiao
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
16.57-17.08
ASSOCIATION BETWEEN CHROMOSOME STABILITY, HPV AND
PROGNOSIS IN TONSILLAR CARCINOMA
JJ Mooren, SMH Claessen, A Haesevoets, Ahn Hopman, Fcs Ramaekers, JP Klussmann, JJ
Manni, B Kremer, EJM Speel
17.08-17.19
ADENOID-CYSTIC CARCINOMAS OF SALIVARY GLANDS ARE
ASSOCIATED WITH HIGH-RISK HPV
AE Albers, C Chen, M Hummel, E Glastetter, U Keilholz, AM Kaufmann
17.19-17.30
NATURAL HISTORY OF ORAL AND ANAL HPV INFECTION.
G D´ Souza, E Sugar, M Gillison
2009-05-13
SESSION 18: TRANSFORMATION AND CARCINOGENESIS
08.30-09.05
ROLES OF VIRAL AND HOST FACTORS IN CERVICAL CANCER
P Lambert
09.05-09.16
MODULATION OF P63 IN CERVICAL CARCINOMA AND REGULATION BY E6
F Thierry, Y Ben Khalifa, M M Tan, D S Toh, S Teissier, M Daynac
09.16-09.27
CUTANEOUS HPV38 INDUCES STABILIZATION OF DELTANP73ALPHA BY
A NOVEL MECHANISM
r accardi
09.27-09.38
ONCOGENE DISRUPTION OF CELL-CELL SENSING UNDERLIES
PHENOTYPIC CHANGE DURING NEOPLASIA
J Doorbar, Erin Isaacson, Ken Raj, Q Wang, D Jackson
09.38-09.49
INDUCTION OF GENOMIC INSTABILITY BY THE HPV16 E7 ONCOPROTEIN
I Hoffmann, R Bahtz, M Arnold, A Krause, O Cizmecioglu, F Settele
09.49-10.00
IDENTIFICATION AND FUNCTIONAL INVESTIGATION OF GENES INVOLVED
IN CERVICAL CARCINOGENESIS
M Liesenfeld, B. Rudolph, D Steinbach, L Jansen, S. Mosig, H. Funke, I Runnebaum, M
Dürst, C Backsch
SESSION 19: TREATMENT AND POST-TREATMENT FOLLOW-UP
11.00-11.11
DEVELOPING OPTIMUM FOLLOW-UP STRATEGIES AFTER CIN
TREATMENT; A SCORING SYSTEM(FUSS)
M Kyrgiou, G Koliopoulos, I Tsoumpou, P Martin - Hirsch, M Arbyn, E Paraskevaidis
11.11-11.22
HC2 AS TEST OF CURE IN STAGE IA CERVICAL CANCER
M Sideri, S Costa, S Boveri, C Casadio, M Sandri, N Spolti, G Negri
11.22-11.33
LONG-TERM INCIDENCE/MORTALITY OF CERVICAL OR VAGINAL
CANCER AFTER CIN3-TREATMENT
B Strander, J Hällgren, P Sparén
11.33-11.44
MORTALITY AFTER TREATMENT OF CERVICAL INTRAEPITHELIAL
NEOPLASIA
I Kalliala, T Dyba, P Nieminen, T Hakulinen, A Anttila
11.44-11.55
POST-TREATMENT HPV TESTING AND LONG-TERM RISK AT
RECURRENCE
M Kocken, JA Louwers, WA ter Harmsel, J Berkhof, PJ Snijders, RHM Verheijen, T
Helmerhorst, CJLM Meijer
11.55-12.06
HPV TESTING IN THE FOLLOW-UP AFTER CONIZATION
A Trope, K Sjøborg, A Eskild, T Eriksen, C Jonassen, U Westerhagen, AK Lie
12.06-12.17
HPV TEST OF CURE REMAINS HIGHLY PREDICTIVE AT 5YRS FOLLOW-UP
H Kitchener, C Moore, R Hadwin, L Nelson, P Walker, A Sargent, J Wood, GB Anthony, M
Cruickshank
12.17-12.28
SURVEILLANCE AFTER TREATMENT FOR CIN: HPV TESTING IS NOT
COST-EFFECTIVE
J Melnikow, S Kulasingam, M Kuppermann, LJ Helms, C Slee, G Sawaya
SESSION 20: HPV-BASED SCREENING I
14.00-14.13
FOLLOW-UP OF THE NTCC RANDOMISED CONTROLLED TRIAL.
G Ronco, N Segnan, A Gillio - Tos, R Rizzolo, A Del Mistro, M Zorzi, P Dalla Palma, F
Carozzi, C Naldoni, M Confortini, P Pierotti, P Giorgi Rossi, J Cuzick
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
14.13-14.24
DURABLE BENEFITS OF HPV-BASED SCREEN-AND-TREAT TO 36 MONTHS
T Wright, L Denny, M DeSousa, L Kuhn
14.24-14.35
HART: LONG-TERM FOLLOW-UP AMONG WOMEN SCREENED BY
CYTOLOGY AND HPV TESTING
J Cusick, D Mesher, A Szarewski, L Cadman, H Cubie, G Hulman, H Kitchener, D Luesley, U
Menon, G Terry, M Desai, C Gie, L Ho, C Pickles, P Sasieni
14.35-14.46
COST-EFFECTIVENESS OF HPV DNA SCREENING IN NON-VACCINATED
AND VACCINATED WOMEN
J Berkhof, VM Coupé, JA Bogaards, Fj van Kemenade, PJ Snijders, CJlm Meijer
14.46-14.57
COST-EFFECTIVENESS OF VARIOUS CERVICAL SCREENING MODALITIES
IN RURAL CHINA
K Canfell, JF Shi, Y Ning, JB Lew, R Legood, FH Zhao, YJ Kang, L Ma, L Simonella, M
Smith, YZ Zhang, JF Chen, M Clements, G Clifford, S Francheschi, Y Qiao
14.57-15.08
ADDITION OF HRHPV TESTING TO CONVENTIONAL CYTOLOGICAL
SCREENING: VUSA-SCREEN TRIAL
D Rijkaart, J Berkhof, PJ Snijders, CJLM Meijer
15.08-15.19
AGE-SPECIFIC PERFORMANCE OF HPV DNA TEST IN PRIMARY CERVICAL
SCREENING
A Anttila, M Leinonen, P Nieminen, L Kotaniemi - Talonen, N Malila, J Tarkkanen, P Laurila
15.19-15.30
HPV TESTING CAN EXTEND SCREENING INTERVALS; EVIDENCE FROM
ARTISTIC TRIAL.
C Thomson, H Baysson, M Almonte, M Desai, A Sargent, A Turner, A Bailey, J Peto
SESSION 21: HPV-BASED SCREENING II
15.30-15.40
PREVENTION BY OFFERING HRHPV-TESTING ON SELF-SAMPLED
CERVICOVAGINAL SPECIMENS TRIAL (PROHTECT)
M Gök, DAm Heideman, FJ Van kemenade, L Rozendaal, J Berkhof, PJ Snijders, CJLM
Meijer
15.40-15.50
NATURAL HISTORIES OF HPV DEFINED BY SELF-SAMPLING
AB Moscicki, L Widdice, Y Ma, S Farhat, S Miller - Benningfield, J Jonte, J Jay, C Godwin -
de Medina, E Hanson, L Clayton, J Simington, S Shiboski
15.50-16.00
TYPE-SPECIFIC HUMAN PAPILLOMAVIRUS (HPV) STRATIFIED BY
ENDOCERVICAL AND VAGINAL SELF-TEST
RG Pretorius, Y Qiao, JL Belinson, H Wang, J Smith, J Li, F Taddeo, S Hu, RJ Burchette
16.00-16.10
TYPING FOR TRIAGING HPV POSITIVE WOMEN AND EXPECTED
VACCINATION EFFECT
F Carozzi, G Ronco, A Del Mistro, L De Marco, S Girlando, M Zorzi, P Dalla palma, C
Naldoni, M Confortini, P Giogi Rossi, J Cuzick, R Rizzolo, N Segnan, A Gillio - Tos
16.10-16.20
HPV TESTING AND CYTOLOGY IN PRIMARY SCREENING IN RURAL CHINA
FH Zhao
16.20-16.30
TRIAGE OF ASCUS/LSIL: META-ANALYSIS OF HPV TEST POSITIVITY RATE
M Arbyn, P Martin - Hirsch, F Buntinx, E Paraskevaidis
SESSION 22: ACCEPTABILITY, BEHAVIOURIAL AND PSYCHOLOGICAL ASPECTS OF K1-3
SCREENING AND VACCINATION
08.30-08.43
COLPOSCOPY AFTER CERVICAL DYSPLASIA: PSYCHOLOGICAL
ASPECTS
C Hellsten, K Sjöström, P Lindqvist
08.43-08.54
U.S. PHYSICIANS’ RECOMMENDATIONS ON SCREENING INTERVALS AND
HPV DNA TESTING
M Saraiya, Z Berkowitz, R Yabroff, V Benard, L Wideroff, S Kobrin
08.54-09.05
ASCCP GUIDELINE ADHERENCE ON MANAGEMENT OF DISCORDANT AND
ASCUS/HPV - RESULTS
M Saraiya, Z Berkowitz, V Benard, L Wideroff, S Kobrin
09.05-09.16
ATTITUDES TO HPV VACCINATION AMONG PARENTS TO CHILDREN 12-15
YEARS
P Sparén, C Young, C Lundholm, T Tran, L Arnheim Dahlström
09.16-09.27
SOCIO-CULTURAL ISSUES FOR INTRODUCTION OF HPV VACCINE IN
LOW-RESOURCE SETTINGS
DS LaMontagne, A Bingham, JK Drake, L Menezes
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.27-09.38
EARLY UPTAKE OF HPV VACCINATION IN GERMANY
SJ Klug, M Claus, A Ahmad, J König, M Blettner
09.38-09.49
RISK PERCEPTIONS AFTER HPV VACCINATION
JA Kahn, SL Rosenthal, C Morrow, M Shew, DI Bernstein, GD Zimet
09.49-10.00
CHALLENGES OF DELIVERING SCHOOL-BASED HPV VACCINATION IN
MANCHESTER, UK
L Brabin, S Roberts, R Stretch, D Baxter, G Chambers, H Kitchener, R McCann
SESSION 23: TRANSFORMATION AND CARCINOGENESIS II
11.00-11.13
CELLULAR ZINC HOMEOSTASIS AS A NATURAL ANTI-HPV BARRIER
M Lazarczyk, P Cassonnet, C Pons, Y Jacob, M Favre, M Lazarczyk, m Lazarczyk
11.13-11.24
NFX1-123 INCREASES HTERT POST-TRANSCRIPTIONALLY IN HPV 16E6-
KERATINOCYTES
R Katzenellenbogen, P Vliet, D Galloway
11.24-11.35
PI3K SIGNALLING DURING HPV MEDIATED TRANSFORMATION IN VITRO
Fe Henken, Pj Snijders, Cjlm Meijer, Rdm Steenbergen
11.35-11.46
PHOSPHORYLATION OF HSCRIB REGULATES ITS INTERACTION WITH
HPV E6 ONCOPROTEINS.
K Nagasaka, L Banks
11.46-11.57
DOWN-MODULATION OF THE P53-NOTCH1 PATHWAY BY HPV-16 E6
T Yugawa, M Narisawa - Saito, M Fujita, T Kiyono
11.57-12.08
IDENTIFICATION OF THE NUCLEAR TRANSPORT SIGNALS OF HPV16 E7
ONCOPROTEIN
J Moroianu, A Knapp, P McManus, K Bockstall, Z Piccioli
12.08-12.19
CUTANEOUS HPV38E7 INTERACTS WITH HUMAN EEF1A AND
MODULATES ITS FUNCTIONS
B Sylla, J. Yue, I. Zanella - Cleon, R. Accardi - Gheit, I. Hussain, M. Becchi, E Oswald, A
Alonso, M Tommasino
12.19-12.30
HPV-16 INFECTION ALTERS CELLULAR MICRORNA EXPRESSION IN
SCCHN
AI Boster, RL Ferris, SA Khan
SESSION 24: VIRAL PROTEINS: STRUCTURE AND FUNCTION
14.00-14.11
HPV18 E2 PROTEIN STABILITY IS CELL-CYCLE DEPENDENT
S Bellanger, C L Tan, W L Nei, P He, F Thierry
14.11-14.22
POST-TRANSLATIONAL MODIFICATION REGULATES HPV16 E1^E4
PROTEIN STRUCTURE AND FUNCTION
J Khan, P McIntosh, C Davy, S Hinz, J Doorbar
14.22-14.33
MODIFICATION OF HPV18 E1^E4 BY PROTEOLYSIS,CDK AND PKA
PHOSPHORYLATION.
A Pugh, G KNIGHT, I BELL, S ROBERTS
14.33-14.44
UP-REGULATION OF P18INK4C EXPRESSION BY HPV E6 VIA P53-MIR-34A
PATHWAY
X Wang, Z-m Zheng
14.44-14.55
INTERACTION OF THE E8^E2C REPRESSOR-PROTEIN WITH THE
CELLULAR CHD6 PROTEIN
J Fertey, T Iftner, F Stubenrauch
14.55-15.06
USE OF A LUCIFERASE FUSION TO STUDY HPV E2 DEGRADATION
D Gagnon, S Joubert, H Sénéchal, A Fradet - Turcotte, S Torre, J Archambault
15.06-15.17
INTERACTION OF BETA PAPILLOMAVIRUS E2 TETHERING PROTEINS
WITH MITOTIC CHROMOSOMES
A McBride, A Poddar, V Sekhar
SESSION 25: PROPHYLACTIC VACCINES (BASIC SCIENCES)
15.20-15.31
IN VIVO MECHANISMS OF PROTECTION BY VLP AND L2 VACCINATION
J Schiller, RC Kines, C Thompson, S Jagu, R Roden, D Lowy, P Day
15.31-15.42
STRUCTURAL AND IMMUNOLOGIC ANALYSIS OF DIFFERENTLY MODIFIED
HPV16 L1 CAPSOMERES
L Schädlich, B Gerlach, T Senger, N Mücke, C Klein, I Bravo, M Müller, L Gissmann
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
15.42-15.53
HPV16 ANTIBODY EPITOPES FROM VACCINE RECIPIENTS AND
FOLLOWING NATURAL INFECTIONS
GC Wipf, JJ Carter, LA Koutsky, D Galloway
15.53-16.04
ANTIBODY RESPONSES IN ORAL FLUID AND SERUM FOLLOWING HPV
VACCINATION
JJ Carter, A Rowhani - Rahbar, Se Hawes, Jp Hughes, La Koutsky, d Galloway
16.04-16.15
RECOGNITION PATTERN OF NEUTRALIZING AND NON-NEUTRALIZING
ANTI-L2 ANTIBODIES
M Müller, A Bolchi, M Tommasino, S Ottonello, I Rubio
16.15-16.26
CHIMERIC L1/L2 VIRUS-LIKE PARTICLES (VLP) AS POTENTIAL BROAD-
SPECTRUM HPV VACCINES
C Schellenbacher, R Roden, R Kirnbauer
2009-05-14
SESSION 26: MOLECULAR MARKERS & HPV TESTING METHODS
08.30-08.40
DIAGNOSTIC HPV16 RNA PATTERN DISCRIMINATING MILD AND SEVERE
CERVICAL LESIONS
M Schmitt, V Dalstein, T Waterboer, C Clavel, L Gissmann, M Pawlita
08.40-08.50
CAN IMMUNOHISTOCHEMISTRY FIX THE DIAGNOSTIC INTERPRETIVE
PROBLEMS WITH CERVICAL BIOPSIES?
M Stoler, K Atkins, M Galgano, W Brix, S Nassau, P Castle
08.50-09.00
E6/E7 MRNA AND DNA TESTS FOR DETECTION OF ≥CIN II
S Ratnam, F Coultee, D Fontaine, J Bentley, N Escott, P Ghatage, G Holloway, E Bartellas,
N Kum, C Giede, V Gadag, A Lear
09.00-09.10
COMPARISON OF MEASURES OF VIRAL PERSISTENCE TO PREDICT
SUBSEQUENT DISEASE
J Gage, M Schiffman, D Solomon, P Castle
09.10-09.20
ABSOLUTE RISK OF SUBSEQUENT CIN3+ ACCORDING TO DIFFERENT
HPV TYPES
S Kjær, C Munk, K Frederiksen, J Junge, T Iftner
09.20-09.30
AMPLICOR HPV DETECTION IN THE ASCUS-LSIL TRIAGE STUDY
N Wentzensen, P Gravitt, D Solomon, C Wheeler, PE Castle
09.30-09.40
EVALUATION OF ABBOTT HIGH RISK HPVDNA ASSAY IN PRIMARY HPV-
SCREENING
B Hammas, J Dillner, C Wahlström
09.40-09.50
P16INK4A IN CERVICAL CYTOLOGY AND HISTOLOGY: SYSTEMATIC
REVIEW AND META-ANALYSIS
I Tsoumpou, M Arbyn, M Kyrgiou, N Wentzensen, G Koliopoulos, P Martin - Hirsch, V
Malamou - Mitsi, E Paraskevaidis
09.50-10.00
DIGENE HPV GENOTYPING LQ-TEST: HIGH-THROUGHPUT GENOTYPING
USING XMAP TECHNOLOGY
D Geraets, DAM Heideman, M de Koning, PJ Snijders, DCJG van Alewijk, CJLM Meijer, Lj
van Doorn, W Quint
SESSION 27: HPV INFECTION IN MALES
11.00-11.11
QUADRIVALENT HPV VACCINE EFFICACY IN MEN HAVING SEX WITH MEN
J Palefsky, A Giuliano
11.11-11.22
CORRELATES OF PERSISTENT INCIDENT GENITAL HPV INFECTION IN
YOUNG MEN
Y Arima, J Partridge, R Winer, S-K Lee, Q Feng, Jp Hughes, M Stern, S O’Reilly, La Koutsky
11.22-11.33
HPV IN DANISH MEN. ASSOCIATION WITH CIRCUMCISION-STATUS AND
GENITAL WARTS
S Kjær, C Munk, B Nøhr, A Nielsen, K Liaw, T Iftner
11.33-11.44
PROBABILITY OF HPV TRANSMISSION AMONG NEWLY-FORMED
COUPLES
A Burchell, J Hanley, P Tellier, F Coutlée, E Franco
11.44-11.55
CONDOM USE IS ASSOCIATED WITH LOWER HPV PREVALENCE IN MEN
CM Nielson, RB Harris, A Nyitray, EF Dunne, KM Stone, A Giuliano
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
11.55-12.06
INTERNATIONAL HPV INCIDENCE AMONG MEN AGES 18-70 YEARS
A Giuliano, JH Lee, WJ FULP, LL Villa, E Lazcano, M Papenfuss, D Smith, M Abrahamsen
12.06-12.17
CONDOMS PREVENT INCIDENT ANAL HUMAN PAPILLOMAVIRUS
INFECTION IN MEN
P Chin - Hong, E Vittinghoff, D Benet, S Buchbinder, M Da Costa, T Darragh, F Judson, B
Koblin, K Mayer, J Palefsky
12.17-12.28
HIGH ANAL HPV PREVALENCE IN MULTINATIONAL SAMPLES: THE HIM
STUDY
A Nyitray, D Smith, L Villa, E Lazcano - Ponce, M Abrahamsen, A Giuliano
SESSION 28: BEST POSTER LECTURES
13.30-13.40
BEST POSTER AWARDS
13.40-13.50
BEST POSTER AWARD LECTURE NUMBER 1
to be annonunced
13.50-14.00
BEST POSTER AWARD LECTURE NUMBER 2
to be annonunced
SESSION 29: LATE BREAKER ABSTRACTS
14.00-14.10
CROSS-PROTECTIVE EFFICACY OF CERVARIX™ AGAINST ONCOGENIC
HPV TYPES BEYOND HPV-16/18.
R Skinner, D Apter, SN Chow, C Wheeler, G Dubin, for the HPV PATRICIA Study Group
14.10-14.20
RAPID DECLINE IN WARTS AFTER NATIONAL QUADRIVALENT HPV
VACCINE PROGRAM
C Fairley, J Hocking, M Chen, B Donovan, C Bradshaw
14.20-14.30
DEFICIENCY IN THE FANCOMNI ANEMIA PATHWAY SENSITIZES MICE TO
HPV-ASSOCIATED HEAD AND NECK CANCER
J W Park, K Strati, P Lambert
14.30-14.40
ARE 2 DOSES OF HPV VACCINE ADEQUATE IN GIRLS ?
S Dobson, M Dawar, D Scheifele, T Kollmann, S McNeil, S Halperin, J Langley, M Dionne,
M-E Picard, C Sauvageau, M Krajden, F Marra, D Miller, D Money, M Naus, G Ogilvie, J
Singer, J Bettinger, E Young
14.40-14.50
CERVICAL CANCER AMONG IMMIGRANTS IN SWEDEN, FROM 1968
THROUGH 2004
F Azerkan, K Zendehdel, P Tillgren, E Faxelid, P Sparén
14.50-15.00
FINAL PHASE III EFFICACY ANALYSIS OF CERVARIX™ IN YOUNG WOMEN
J Paavonen, P Naud, J Salmerón, C Wheeler, S-N Chow, D Apter, H Kitchener, X
Castellsague, J Teixeira, SR Skinner, J Hedrick, U Jaisamrarn, G Limson, SM Garland, A
Szarewski, B Romanowski, F Aoki, T Schwarz, WAJ Poppe, X Bosch, D Jenkins, K Hardt, T
Zahaf, D Descamps, F Struyf, M Lehtinen, G Dubin
SESSION 30: GLOBAL HPV EPIDEMIOLOGY
08.30-08.41
COMPARISON OF SERA AND DRIED BLOOD SPOTS FOR HPV
SEROEPIDEMIOLOGY
T Waterboer, B Dondog, KM Michael, A Michel, M Schmitt, S Franceschi, G Clifford, M
Pawlita
08.41-08.52
CUMULATIVE 2-YEAR HR-HPV PERSISTENCE AND ACQUISITION IN PERI-
URBAN INDIAN WOMEN
P Gravitt, H Vedantham, P Paul, B Kalpana, D Vidyadhari, P Sowjanya, G Ramakrishna, K
Vijayaraghavan, K Shah
08.52-09.03
SEROPREVALENCE OF HPV 6, 11, 16, 18 IN UNITED STATES
Le Markowitz, M Sternberg, Ef Dunne, Er Unger
09.03-09.14
AGE-SPECIFIC PREVALENCE OF PRECANCEROUS LESIONS OF THE
CERVIX: GLOBAL REVIEW
J Ting, DT Kruzikas, J Smith
09.14-09.25
WORLDWIDE HPV TYPE-SPECIFIC PREVALENCE IN CYTOLOGICALLY
NORMAL WOMEN (1995-2008)
L Bruni, E Ferrer, M Diaz, KS Louie, G Albero, J Muñoz, X Castellsagué, F Bosch, S de
Sanjosé
09.25-09.36
HPV 16 AND 18 NEUTRALIZING ANTIBODY IN PRENATAL WOMEN
M Krajden, K Karunakaran, S So, J Palefsky, R Sharma, A Yu, R Chow, S Dobson, G
Ogilvie, M Petric
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
09.36-09.47
HIGH-RISK HPV PERSISTENCE IN DANISH WOMEN FROM THE GENERAL
POPULATION
A Nielsen, S Kjær, C Munk, M Osler, T Iftner
09.47-09.58
POPULATION-BASED SEROPREVALENCE OF HUMAN PAPILLOMAVIRUS
IN CHINESE WOMEN
J Ji, H Wang, W Chen, s Hu, M Esser, C. Velicher, JL Belinson, Rg Pretorius, J Smith, Y
Qiao
SESSION 31: HPV TESTING II
11.00-11.10
THE WHO HPVLABNET INTERNATIONAL PROFICIENCY STUDY OF
HPVDNA TYPING METHODS
C Eklund, T Zhou, J Dillner, and the WHO HPV Laboratory Network
11.10-11.20
NATIONAL QUALITY ASSURANCE PROGRAM FOR HPV-TESTING AND
TYPING IN ITALY
F Carozzi, G Venturini, L Ciccocioppo, A Del Mistro, A Gillio - Tos, S Girlando, L De Marco, H
Frayle, P Giorgi Rossi, G Ronco, M Confortini, C Tufi, C Sani, HPV QA Working Group
11.20-11.30
TRANSCRIPTOME PROFILING OF CERVICAL SWABS FROM
PERSISTENTLY HPV16 INFECTED WOMEN
A Manawapat, S Krüger Kjaer, B Schopp, R Russ, A-M Florea, C Munk, T Iftner, F
Stubenrauch
11.30-11.40
KALLICREIN-7 AND SUPEROXIDE DISMUTASE-2 AS PROGRESSION
MARKERS OF CERVICAL DISEASE
L Termini, PC Maciag, FA Soares, S Nonogaki, VAF Alves, A Longatto - Filho, LL Villa
11.40-11.50
TRIAGE OF ASC-US AND LSIL CYTOLOGY CASES BY P16
IMMUNOCYTOCHEMISTRY
C BERGERON, D KARIN, K PETRA, T MARCUS, R RUDIGER
11.50-12.00
THE USE OF AN RNA-BASED HPV-TEST IN HPV TRIAGING
SW Sørbye, S Fismen, T Gutteberg, ES Mortensen
12.00-12.10
RESULTS OF THE FRENCH APTIMA HPV SCREENING EVALUATION (FASE
STUDY)
J Monsonego, P Halfon, L Zerat, M Ricart, F Ruiz, k Syrjänen
12.10-12.20
A NOVEL BROAD-SPECTRUM PCR-LUMINEX ASSAY FOR IDENTIFICATION
OF WART HPV
M de Koning, J ter Schegget, M Kamp, B Kleter, Mcw Feltkamp, J Eekhof, JN Bouwes
Bavinck, K Purdie, C Harwood, W Quint
12.20-12.30
HPV MRNA AND P16INK4A AS TRIAGE MARKERS IN CERVICAL
CYTOLOGY
M Reuschenbach, A Clad, C von Knebel Doeberitz, J Rahmsdorf, R Grote, L Wu, N
Wentzensen, M von Knebel Doeberitz
SESSION 32: TAXONOMY AND HPV DATABASES
13.30-13.43
PAPILLOMAVIRUS TAXONOMY: REPORT OF THE ICTV STUDY GROUP.
H.U. Bernard, Rd Burk, Em de Villiers, M. van Ranst, H. zur Hausen
13.43-13.54
PAPILLOMAVIRUS EPISTEME (PAVE): A COMPREHENSIVE
PAPILLOMAVIRIDAE DATABASE AND ANALYSIS RESOURCE
Y. Huyen, Y. Mohamoud, V. Gopalan, S. Bandaru, J. Nozzi, J. Barnett, A McBride
13.54-14.05
CHARACTERIZATIONS OF NINE MACACA FASCICULARIS
PAPILLOMAVIRUS (MFPV) COMPLETE GENOMES
K van Doorslaer, Z Chen, C Wood, Rd Burk
14.05-14.16
MODELING CARCINOGENIC HPV GENITAL INFECTIONS AND DISEASE
WITH RHPV1
M Ozbun, J. Maestas, A. Maldonado, N. Patterson, M. Kivitz, N. Joste, P. Marx, V. Traina -
Dorge
14.16-14.27
NOVEL HPV SEQUENCES IN CERVICAL CARCINOMA CONTAINING SINGLE
HPV GENOTYPES
W Quint, D Geraets, N Guimerà, N Guimerà, M de Koning, LJ van Doorn, S de Sanjosé, F
Bosch
14.27-14.38
ALPHA AND BETA PAPILLOMAVIRUSES DIFFER IN SYNONYMOUS CODON
USAGE
N Cladel, A Bertotto, N Christensen,
PROGRAMME
Oral presentations
THE 25TH INTERNATIONAL PAPILLOMAVIRUS CONFERENCE MAY 8-14 2009, MALMÖ,
14.38-14.49
EVOLUTION OF PRIMATE ALPHA PAPILLOMAVIRUSES
Z Chen, K van Doorslaer, R DeSalle, C Wood, Rd Burk
14.49-15.00
TOWARDS A TIME SCALE FOR THE EVOLUTION OF PAPILLOMAVIRUSES
I Bravo, A Stamatakis, O Bininda - Emonds, M Göker, I Nindl, M Gottschling

Source: http://www.hpv2009.org/PresentationProgram090324.pdf